Number of shares and votes in Orexo
Uppsala, Sweden – October 31, 2016 – The number of shares and votes in Orexo AB has changed as a result of the exercise of warrants in connection with the company’s incentive programs and, as previous announced, by issue and repurchase of class C shares.
Today, the last trading day of the month, there are in total 34,870,326 shares - whereof 34,535,326 are ordinary shares and 335,000 class C shares - and 34,568,826 votes in the company.
For further information, please contact:
Orexo AB (publ.)
|Henrik Juuel, EVP and CFO||Lena Wange, IR & Communications Manager|
|Tel: 018 780 88 00||Tel: 018 780 88 00|
|email: firstname.lastname@example.org||email: email@example.com|
Orexo is a specialty pharmaceutical company commercializing its proprietary product Zubsolv® for treatment of opioid dependence in the US. Zubsolv is an advanced formulation of buprenorphine and naloxone using Orexo’s unique knowledge and expertise in sublingual drug delivery. R&D is focusing on reformulation of known substances to new improved products that meet great unmet medical needs by using its patented proprietary technologies. Orexo’s share is listed on Nasdaq Stockholm Exchange Mid Cap (STO: ORX) and is available as ADRs on OTCQX (ORXOY) in the US. Orexo’s global headquarters and R&D are based in Uppsala, Sweden.
For more information about Orexo, please visit www.orexo.com or follow us on Twitter or LinkedIn. For further information about Zubsolv in the US, please visit www.zubsolv.com.
The information was submitted for publication at 6:00pm CET, October 31, 2016